- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/34 - One oxygen atom
Patent holdings for IPC class C07D 239/34
Total number of patents in this class: 579
10-year publication summary
|
50
|
40
|
37
|
34
|
37
|
35
|
26
|
25
|
34
|
24
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4493 |
16 |
| Bristol-myers Squibb Company | 4742 |
15 |
| Syngenta Crop Protection AG | 6701 |
15 |
| Vertex Pharmaceuticals Incorporated | 1582 |
12 |
| Eisai R&D Management Co., Ltd. | 1167 |
12 |
| Takeda Pharmaceutical Company Limited | 2712 |
11 |
| FMC Corporation | 807 |
11 |
| Theravance Biopharma R&D IP, LLC | 362 |
11 |
| Amgen Inc. | 4427 |
10 |
| BASF SE | 21303 |
9 |
| Eonhf, Inc. | 45 |
8 |
| E. I. du Pont de Nemours and Company | 3534 |
6 |
| Bayer AG | 3501 |
6 |
| Bayer Pharma AG | 1014 |
6 |
| Sumitomo Chemical Company, Limited | 9016 |
6 |
| Daiichi Sankyo Company, Limited | 1890 |
6 |
| Vividion Therapeutics, Inc. | 43 |
6 |
| Angelini Pharma S.p.A. | 43 |
6 |
| Novartis AG | 10262 |
5 |
| President and Fellows of Harvard College | 6094 |
5 |
| Other owners | 397 |